JP2011509311A - 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法 - Google Patents

治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法 Download PDF

Info

Publication number
JP2011509311A
JP2011509311A JP2010542394A JP2010542394A JP2011509311A JP 2011509311 A JP2011509311 A JP 2011509311A JP 2010542394 A JP2010542394 A JP 2010542394A JP 2010542394 A JP2010542394 A JP 2010542394A JP 2011509311 A JP2011509311 A JP 2011509311A
Authority
JP
Japan
Prior art keywords
hydrophobic
composition
solution
chain
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010542394A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011509311A5 (OSRAM
Inventor
ジェラルド エム． カスティロ，
エリジャー エム． ボロティン，
Original Assignee
ファーマイン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマイン コーポレイション filed Critical ファーマイン コーポレイション
Publication of JP2011509311A publication Critical patent/JP2011509311A/ja
Publication of JP2011509311A5 publication Critical patent/JP2011509311A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010542394A 2008-01-09 2009-01-09 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法 Withdrawn JP2011509311A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/971,482 US20090176892A1 (en) 2008-01-09 2008-01-09 Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
PCT/US2009/030678 WO2009089506A1 (en) 2008-01-09 2009-01-09 Soluble hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013259956A Division JP5878912B2 (ja) 2008-01-09 2013-12-17 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Publications (2)

Publication Number Publication Date
JP2011509311A true JP2011509311A (ja) 2011-03-24
JP2011509311A5 JP2011509311A5 (OSRAM) 2013-01-31

Family

ID=40845092

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2010542394A Withdrawn JP2011509311A (ja) 2008-01-09 2009-01-09 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2013259956A Active JP5878912B2 (ja) 2008-01-09 2013-12-17 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2014110975A Withdrawn JP2014156486A (ja) 2008-01-09 2014-05-29 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2016104890A Active JP6244400B2 (ja) 2008-01-09 2016-05-26 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2017149174A Active JP6342556B2 (ja) 2008-01-09 2017-08-01 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2013259956A Active JP5878912B2 (ja) 2008-01-09 2013-12-17 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2014110975A Withdrawn JP2014156486A (ja) 2008-01-09 2014-05-29 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2016104890A Active JP6244400B2 (ja) 2008-01-09 2016-05-26 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
JP2017149174A Active JP6342556B2 (ja) 2008-01-09 2017-08-01 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法

Country Status (4)

Country Link
US (3) US20090176892A1 (OSRAM)
EP (1) EP2240165B1 (OSRAM)
JP (5) JP2011509311A (OSRAM)
WO (1) WO2009089506A1 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010100781A (ja) * 2008-10-27 2010-05-06 Josho Gakuen 高分子、経上皮吸収促進剤、及び医薬用製剤
KR20170109526A (ko) * 2014-11-03 2017-09-29 파마인 코포레이션 우수한 펩티드 및 단백질 결합 성질을 갖는 그래프트 공중합체 부형제의 제조 방법

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009520040A (ja) 2005-12-19 2009-05-21 ファーマイン コーポレーション 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
AU2010292329B2 (en) * 2009-09-09 2016-07-21 Pharmain Corporation Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
WO2012051458A1 (en) * 2010-10-14 2012-04-19 Nitto Denko Corporation Nucleic acid delivery compounds
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
WO2018017954A1 (en) * 2016-07-21 2018-01-25 Rutgers, The State University Of New Jersey Antimicrobial cationic systems and methods of use
EP3740227A1 (fr) 2017-12-07 2020-11-25 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3083086A1 (fr) * 2018-06-29 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
WO2019115411A1 (fr) * 2017-12-07 2019-06-20 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
MX2020005916A (es) 2017-12-07 2020-10-19 Adocia Composiciones en forma de una solución acuosa inyectable que comprende amilina, un receptor agonista de amilina o un análogo de amilina y un copoliaminoácido.
WO2019110797A1 (fr) 2017-12-07 2019-06-13 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002194080A (ja) * 2000-12-27 2002-07-10 Mitsui Chemicals Inc 重合体及びその製造方法
US6576254B1 (en) * 1998-05-23 2003-06-10 University Of Strathclyde Polyamino acid vesicles
WO2005115492A1 (en) * 2004-05-25 2005-12-08 Biointeractions Ltd Absorbable biocompatible materials
US20070141145A1 (en) * 2005-12-19 2007-06-21 Pharmaln Ltd. Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849708B1 (en) * 1986-05-05 2005-02-01 The General Hospital Corporation Insulinotropic hormone and uses thereof
US5120712A (en) * 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) * 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US7138486B2 (en) * 1986-05-05 2006-11-21 The General Hospital Corporation Insulinotropic hormone derivatives and uses thereof
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5527524A (en) * 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
US4857311A (en) * 1987-07-31 1989-08-15 Massachusetts Institute Of Technology Polyanhydrides with improved hydrolytic degradation properties
US5681543A (en) * 1988-02-29 1997-10-28 Shering Aktiengesellschaft Polymer-bonded complexing agents and pharmaceutical agents containing them for MRI
US5116603A (en) 1989-01-31 1992-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Oral antifungal preventative, and method of use
US5744166A (en) * 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5837747A (en) * 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
US5770563A (en) * 1991-12-06 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Heparin- and sulfatide binding peptides from the type I repeats of human thrombospondin and conjugates thereof
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
JP4074658B2 (ja) * 1992-04-03 2008-04-09 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 自己構築ポリヌクレオチド送達システム
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
DE69332952T2 (de) * 1992-09-04 2004-02-19 The General Hospital Corp., Boston Diagnostische und therapeutische Einheiten enthaltende biokompatible Polymere
US5395619A (en) * 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5605672A (en) * 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5763585A (en) * 1993-10-13 1998-06-09 Anergen, Inc. Method of making MHC-peptide complexes using metal chelate affinity chromatography
CA2161684C (en) * 1994-03-07 2010-11-09 Larry R. Wilson Bioactive and/or targeted dendrimer conjugates
US5466467A (en) * 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20010006943A1 (en) * 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
US5855610A (en) * 1995-05-19 1999-01-05 Children's Medical Center Corporation Engineering of strong, pliable tissues
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
JPH11507697A (ja) * 1995-06-09 1999-07-06 エヌ． ドロハン，ウィリアム キチンヒドロゲル、それらの製造方法及び利用
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
WO1997014740A1 (en) * 1995-10-19 1997-04-24 Receptagen Corporation Discrete-length polyethylene glycols
CZ297979B6 (cs) 1996-03-12 2007-05-16 Pg-Txl Company, L. P. Kompozice obsahující protinádorové lécivo konjugované s ve vode rozpustným polymerem, její pouzití pro výrobu léciva a implantovatelná lékarská pomucka
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US7235627B2 (en) * 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) * 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6153211A (en) * 1997-07-18 2000-11-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances
US6468532B1 (en) * 1998-01-22 2002-10-22 Genentech, Inc. Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US6509323B1 (en) * 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
EP2028269B1 (en) * 1998-08-10 2015-10-21 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or Exendin-4 and uses thereof
DE69935435T2 (de) * 1998-08-12 2007-12-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Mittels Ammoniumsulfatgradient hergestellte liposomale analgetische Zusammensetzungen
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
BR0008590A (pt) * 1999-01-08 2001-10-30 Emisphere Tech Inc Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
US6365173B1 (en) * 1999-01-14 2002-04-02 Efrat Biopolymers Ltd. Stereocomplex polymeric carriers for drug delivery
IL138990A0 (en) * 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US6926304B2 (en) * 2000-02-22 2005-08-09 Daicel Chemical Industries, Ltd. Airbag generator, deflector member, coolant/filter means support member, coolant, and housing
MXPA02009031A (es) * 2000-03-14 2004-08-19 Amylin Pharmaceuticals Inc Efectos del peptido-1(7-36) tipo glucagon en la motilidad antro-piloro.duodenal.
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US6589549B2 (en) * 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
CN1462191B (zh) * 2000-05-19 2013-07-24 埃米林药品公司 Glp-1用于制备治疗急性冠脉综合征的药物的用途
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
AU8466501A (en) * 2000-07-21 2002-02-05 Essentia Biosystems Inc Multi-component biological transport systems
US20040092432A1 (en) * 2000-08-24 2004-05-13 Thomas Jefferson University Peptide compositions with effects on cerebral health
US6521736B2 (en) * 2000-09-15 2003-02-18 University Of Massachusetts Amphiphilic polymeric materials
AU775663B2 (en) * 2000-10-20 2004-08-12 Amylin Pharmaceuticals, Inc. Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
US7259233B2 (en) * 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002228608A1 (en) * 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
ES2315350T3 (es) * 2001-01-12 2009-04-01 Waratah Pharmaceuticals Inc. Composiciones para la introduccion de la neogenesis de islotes, que contienen unos ligandos para el receptor de gastrina/cck y ligandos para el receptor de efg.
JP2005506956A (ja) * 2001-06-01 2005-03-10 イーライ・リリー・アンド・カンパニー 長時間作用性ｇｌｐ−１製剤
JP5562510B2 (ja) * 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
US6586524B2 (en) * 2001-07-19 2003-07-01 Expression Genetics, Inc. Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier
IL160493A0 (en) * 2001-08-23 2004-07-25 Lilly Co Eli Glucagon-like peptide-1 analogs
PL373846A1 (en) * 2001-10-01 2005-09-19 Eli Lilly And Company Method of reducing mortality and morbidity associated with critical illnesses
US7041646B2 (en) * 2001-10-05 2006-05-09 Bayer Pharmaceuticals Corporation Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists
AU2002349513B2 (en) * 2001-11-26 2007-10-18 Asubio Pharma Co., Ltd. Medicinal compositions for nasal absorption
JP4417113B2 (ja) * 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Ｇｌｐ−１分子の投与方法
ATE494010T1 (de) * 2002-02-27 2011-01-15 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
US6705987B2 (en) * 2002-04-17 2004-03-16 Endocare, Inc. Penile seal and constriction ring
MXPA04012497A (es) * 2002-07-04 2005-07-14 Zealand Pharma As Glp-1 y metodos para tratar la diabetes.
WO2004014451A1 (en) 2002-08-13 2004-02-19 Medtronic, Inc. Active agent delivery systems, medical devices, and methods
AU2003273300A1 (en) 2002-09-06 2004-03-29 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
GB0221941D0 (en) * 2002-09-20 2002-10-30 Univ Strathclyde Polysoaps
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
EP1610765B1 (en) * 2003-03-31 2008-08-13 ALZA Corporation Non-aqueous single phase vehicles and formulations utilizing such vehicles
WO2005000222A2 (en) * 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
EP2292253A3 (en) * 2003-06-03 2011-12-14 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
CN102940879B (zh) * 2003-06-03 2017-06-06 诺沃挪第克公司 稳定化的药物肽组合物
US20060247167A1 (en) * 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
WO2005058252A2 (en) * 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005084180A2 (en) 2003-12-19 2005-09-15 University Of Cincinnati Polyamides and polyamide complexes for delivery of oligonucleotide decoys
US20050143303A1 (en) 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
JP2007527431A (ja) * 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
FR2867679B1 (fr) * 2004-03-17 2008-08-22 Oreal Composition cosmetiques comprenant des polyamines modifiees et utilisations desdites compositions.
US7985424B2 (en) * 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
EP1737899B1 (en) * 2004-04-20 2015-07-08 Dendritic Nanotechnologies, Inc. Dendritic polymers with enhanced amplification and interior functionality
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
JP2008512350A (ja) * 2004-07-01 2008-04-24 イェール ユニバーシティ 標的化され、そして高密度で薬物が負荷されるポリマー性物質
WO2006014425A1 (en) * 2004-07-02 2006-02-09 Biovalve Technologies, Inc. Methods and devices for delivering glp-1 and uses thereof
PT1773878E (pt) * 2004-07-19 2015-06-05 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
KR100675834B1 (ko) * 2004-10-28 2007-01-29 한국전자통신연구원 루프백 형 파장분할다중방식의 수동형 광 네트워크
US20060233857A1 (en) * 2005-04-14 2006-10-19 Amsden Brian G Degradable elastomeric network
WO2007024899A2 (en) 2005-08-23 2007-03-01 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
WO2007030706A1 (en) 2005-09-08 2007-03-15 New England Medical Center Hospitals, Inc. Fragments of the glucagon-like peptide-i and uses thereof
EP1931397B1 (en) * 2005-10-05 2009-04-08 SCA Hygiene Products AB Absorbent article comprising hydrophilic and hydrophobic regions
ES2625109T3 (es) 2005-10-25 2017-07-18 Starpharma Pty Limited Compuestos macromoleculares que tienen estequiometría controlada
HRP20160866T1 (hr) 2005-11-04 2016-10-07 Glaxosmithkline Llc Postupci primjene hipoglikemijskih sredstava
CN104524596B (zh) 2006-01-20 2018-10-09 星药股份有限公司 经修饰的大分子
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576254B1 (en) * 1998-05-23 2003-06-10 University Of Strathclyde Polyamino acid vesicles
JP2002194080A (ja) * 2000-12-27 2002-07-10 Mitsui Chemicals Inc 重合体及びその製造方法
WO2005115492A1 (en) * 2004-05-25 2005-12-08 Biointeractions Ltd Absorbable biocompatible materials
US20070141145A1 (en) * 2005-12-19 2007-06-21 Pharmaln Ltd. Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010100781A (ja) * 2008-10-27 2010-05-06 Josho Gakuen 高分子、経上皮吸収促進剤、及び医薬用製剤
KR20170109526A (ko) * 2014-11-03 2017-09-29 파마인 코포레이션 우수한 펩티드 및 단백질 결합 성질을 갖는 그래프트 공중합체 부형제의 제조 방법
JP2018505230A (ja) * 2014-11-03 2018-02-22 ファーマイン コーポレイション 優れたペプチドおよびタンパク質結合特性を備えたグラフトコポリマー賦形剤の生成の方法
KR102369119B1 (ko) 2014-11-03 2022-02-28 파마인 코포레이션 우수한 펩티드 및 단백질 결합 성질을 갖는 그래프트 공중합체 부형제의 제조 방법

Also Published As

Publication number Publication date
JP6244400B2 (ja) 2017-12-06
JP2014058562A (ja) 2014-04-03
US8999930B2 (en) 2015-04-07
JP2014156486A (ja) 2014-08-28
US9562111B2 (en) 2017-02-07
EP2240165B1 (en) 2019-03-06
US20090176892A1 (en) 2009-07-09
WO2009089506A1 (en) 2009-07-16
EP2240165A4 (en) 2013-05-22
JP2016153429A (ja) 2016-08-25
US20100234279A1 (en) 2010-09-16
US20150284476A1 (en) 2015-10-08
JP2017190357A (ja) 2017-10-19
JP5878912B2 (ja) 2016-03-08
EP2240165A1 (en) 2010-10-20
JP6342556B2 (ja) 2018-06-13

Similar Documents

Publication Publication Date Title
JP6342556B2 (ja) 治療薬送達のための可溶性疎水性コア担体組成物、およびその製造・使用方法
AU2015242970B2 (en) Glycopolysialylation of non-blood coagulation proteins
KR101759300B1 (ko) 비혈액 응고 단백질의 글리코폴리시알화
CN104906594B (zh) 用于与蛋白质和肽缀合的四个支链的树枝状大分子peg
EP3449946A2 (en) Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
JP2022058911A (ja) 非血液凝固タンパク質の糖ポリシアル酸化
Salmaso et al. Nanotechnologies in protein delivery
Tuesca et al. Synthesis, characterization and in vivo efficacy of PEGylated insulin for oral delivery with complexation hydrogels
WO2010057774A1 (en) Site-specific monoconjugated insulinotropic glp-1 peptides
US20060286657A1 (en) Novel bioconjugation reactions for acylating polyethylene glycol reagents
HARTNER et al. ANATOLY N. LUKYANOV, RISHIKESH M. SAWANT
Orlando Modification of proteins and low molecular weight substances with hydroxyethyl starch (HES): HESylation-a new technology for polymer conjugation to biologically active molecules
HK1230072A1 (en) Conjugate comprising erythropoietin and a branched polymer structure
CN106163541A (zh) 包含促红细胞生成素和支化聚合物结构的缀合物
HK1171667B (en) Glycopolysialylation of proteins other than blood coagulation proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130717

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140228

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20140304